Apollo's development of biologic therapeutics stems from three main technologies. The first two technologies revolve around oral and transdermal delivery of biopharmaceutical drugs based on such large molecules as proteins and antibodies. This needle-free delivery aims to improve patient convenience and comfort. The third technology involves the production of more natural recombinant human proteins, allowing the creation of biopharmaceutical drugs that are more effective, require lower and less frequent doses, and have fewer side effects. Each technology can individually form the basis of new or better treatments for a range of diseases where there are significant unmet needs. In combination, they are potentially transforming.

Apollo's oral delivery technology, Oradel™, combines the ability to protect a therapeutic protein from the harsh stomach environment with actively promoting transport of the drug into the bloodstream. By contrast, many drugs, particularly proteins, must currently be injected, as oral delivery can be inefficient: the proteins are either digested in the intestine or pass down the intestine without being absorbed, and end up in the bowel. However, there is demand for a delivery method to replace injections: many patients may currently avoid medication, simply because they don't like needles.

Apollo's TransD™ transdermal delivery technology overturns the long-held view that large water or oil soluble molecules such as proteins and antibodies, in contrast to smaller chemical compounds, cannot penetrate the skin.

Apollo's non-invasive transdermal carrier, TransD™, is based on a proprietary formulation that is able to deliver a protein-laden water layer across the skin and into the surrounding dermal and sub-dermal layers. A key advantage TransD™ offers over competing transdermal delivery technologies is its ability to deliver a significantly wider range of molecules than existing transdermal technologies in terms of size and water or oil solubility.

Apollo has developed technology that allows it to produce recombinant human proteins that are expected to offer therapeutic benefits because they more closely mimic proteins in the human body. Anticipated benefits include better patient experience, lower side effects and better efficacy. The company's extensive range of human-expressed (hcx™) proteins forms a target-rich bank of candidates that can be selected, refined and developed into biopharmaceuticals to treat a wide range of diseases.